Head and Neck Squamous Cell Carcinomas Do Not Express EGFRvIII

Lieuwe J Melchers, Martijn J A M Clausen, Mirjam F Mastik, Lorian Slagter-Menkema, Johannes A Langendijk, Bernard F A M van der Laan, Jacqueline E van der Wal, Bert van der Vegt, Jan L N Roodenburg, Ed Schuuring

OnderzoeksoutputAcademicpeer review

9 Citaten (Scopus)


Purpose: To assess the prevalence of EGFRvIII, a specific variant of EGFR (epidermal growth factor receptor), in 3 well-defined cohorts of head and neck squamous cell carcinoma (HNSCC).

Methods and Materials: Immunohistochemistry for the specific detection of EGFRvIII using the L8A4 antibody was optimized on formalin-fixed, paraffin-embedded tissue using glioblastoma tissue. It was compared with EGFR and EGFRvIII RNA expression using a specific reverse transcription-polymerase chain reaction also optimized for formalin-fixed, paraffin-embedded tissue. Tissue microarrays including 531 HNSCCs of various stages with complete clinicopathologic and follow-up data were tested for the presence of EGFRvIII.

Results: None of the 531 cases showed EGFRvIII protein expression. Using an immunohistochemistry protocol reported by others revealed cytoplasmic staining in 8% of cases. Reverse transcription-polymerase chain reaction for the EGFRvIII transcript of the 28 highest cytoplasmic staining cases, as well as 69 negative cases, did not show expression in any of the tested cases, suggesting aspecific staining by a nonoptimal protocol.

Conclusions: The EGFRvIII mutation is not present in HNSCC. Therefore, EGFRvIII does not influence treatment response in HNSCC and is not a usable clinical prognostic marker. (C) 2014 Elsevier Inc.

Originele taal-2English
Pagina's (van-tot)454-462
Aantal pagina's9
TijdschriftInternational Journal of Radiation Oncology, Biology, Physics
Nummer van het tijdschrift2
StatusPublished - 1-okt-2014

Citeer dit